硝酸铈(3+)铵 | 15318-60-2

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 镧系含氧阴离子化合物
• 中文名称: 硝酸铈(3+)铵
• 中文别名: 硝酸铈(3+)铵(5:1:2)
• 英文名称: ammonium cerium (III) nitrate
• 英文别名: cerium ammonium nitrate；ceric ammonium nitrate；ammonium cerium nitrate；Nitric acid, ammonium cerium(3+) salt (5:2:1)；azanium;cerium(3+);nitrate
• CAS: 15318-60-2
• 化学式: Ce*H₄N*4NO₃
• 分子量: 406.178
• InChiKey: OSYLPIYJUCCMTQ-UHFFFAOYSA-O

物化性质

• 熔点：
  74℃ [CRC10]

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  硝酸铈(3+)铵 在 C₅H₅Na 作用下， 以 四氢呋喃 为溶剂， 以77%的产率得到Cp₃Ce(THF)
  参考文献：
  名称：

  Gradeff, Peter S.; Yunlu, Kenan; Deming, Timothy J., Inorganic Chemistry, 1989, vol. 28, # 13, p. 2600 - 2604

  摘要：

  DOI：
• 作为产物：
  描述：

  cerous ammonium nitrate tetrahydrate 以 neat (no solvent) 为溶剂， 生成 硝酸铈(3+)铵
  参考文献：
  名称：

  Audebrand, Nathalie; Auffredic, Jean-Paul; Louer, Daniel, Thermochimica Acta, 1997, vol. 293, # 1-2, p. 65 - 76

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-羟基-4,5-二氟苯甲醛 在 硝酸铈(3+)铵 、 三氟化硼乙醚 、 potassium carbonate 、 potassium iodide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 正庚烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.75h， 生成 3-(1-fluoro-1-methylethyl)-6,7-difluoro-4-(N-Boc-methylaminoethynyl)chromane
  参考文献：
  名称：

  A highly diastereoselective series of Nicholas cyclisation reactions of N-Boc-protected propargylamines

  摘要：

  The reaction of N-Boc-protected propargylamine with salicylaldehyde derivatives and their subsequent Nicholas cyclisation reaction to provide a range of novel benzopyrans is reported. The cyclisation reactions proceeded with excellent levels of diastereoselectivity to afford compounds with cis-relative stereochemistry. As far as we are able to ascertain these are the first reported examples of Nicholas cyclisation reactions of propargyl alcohols that bear a terminal alkynyl N-protected amino motif. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.08.087

文献信息

• CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20140088117A1

  公开（公告）日：2014-03-27

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I的环醚吡唑-4-基-杂环基-羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2为环醚，X为噻唑基、吡啶基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
• 1,2 diarylbenzimdazoles and their pharmaceutical use
  申请人：Schering AG

  公开号：US20020006948A1

  公开（公告）日：2002-01-17

  Benzimidazoles of general formula I 1 and the use of benzimidazole derivatives for the production of pharmaceutical agents for treatment and prophylaxis of diseases that are associated with a microglia activation are described.

  通用公式I的苯并咪唑及其衍生物的使用用于生产与微胶质细胞活化相关的疾病的药物制剂，用于治疗和预防这些疾病。
• Antitumour 1,5-diazaanthraquinones
  申请人：——

  公开号：US20020099066A1

  公开（公告）日：2002-07-25

  1 Compounds having formula (I) wherein R 3 , R 4 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, lower alkyl, halogen, amine, mono(lower)alkylamine, di(lower)alkylamine, phenyl, or substituted phenyl possess antitumor activity and are new with the exception of the compound in which R 3 , R 4 , R 7 , R 8 are all hydrogen and the compound in which R 3 and R 7 are hydrogen, R 4 chlorine, and R 8 is a 2-nitrophenyl group.

  具有公式(I)的化合物，其中R3、R4、R7和R8独立地选自包括氢、低级烷基、卤素、胺、单（低级）烷基胺、二（低级）烷基胺、苯基或取代苯基的组，具有抗肿瘤活性，除了R3、R4、R7、R8均为氢的化合物和R3和R7为氢，R4为氯，R8为2-硝基苯基的化合物外，都是新的。
• Reverse hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US06294573B1

  公开（公告）日：2001-09-25

  Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

  具有以下化学式的化合物是基质金属蛋白酶抑制剂。还公开了抑制基质金属蛋白酶的组合物和方法，用于在哺乳动物中抑制基质金属蛋白酶。
• NOVEL PYRIMIDINE DERIVATIVE AND NOVEL PYRIDINE DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP1318147A1

  公开（公告）日：2003-06-11

  Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels.

  非手性嘧啶衍生物和以下结构式或其类似物的吡啶衍生物具有选择性N型钙通道拮抗活性，并且当口服时表现出镇痛作用。它们可用作与N型钙通道相关的疼痛和各种疾病的治疗药物。